MKI67 and neoplasm: Previous studies evaluating Ki-67 expression in malignant tumor tissues have used benign masses [27-29], hyper/dysplastic lesions [27-30], normal tissues from similar areas in different patients [28, 30, 31] or normal tissues from similar areas in same patients [29, 32] as comparative non-malignant tissues, but few studies have evaluated juxtaposed normal peri-tumoral tissues to document significant protein biomarker up-regulation by tumors.